Featured Research

from universities, journals, and other organizations

Epileptic or non-epileptic seizures? Misdiagnosis common

Date:
April 28, 2014
Source:
University of California - Los Angeles Health Sciences
Summary:
A research team set out to estimate the probability of epilepsy versus non-epileptic seizures based on the historical factors reported by the patient to their neurologist. Distinguishing between epileptic and non-epileptic seizures is a challenge, according to experts. On average, the time from the first seizure to the diagnosis of non-epileptic seizures is seven years. In the meantime, a majority of those patients are misdiagnosed with epilepsy and treated inappropriately with anti-epileptic medications.

A graduate student in Semel Institute for Neuroscience and Human Behavior, and two of his undergraduate trainees, were selected by the Council on Undergraduate Research to present their original research on Capitol Hill in Washington, D.C., on April 29.*

Wesley Kerr, whose graduate studies will be completed in the UCLA Department of Biomathematics, and his trainees, Akash Patel and Sarah Barritt, will present their poster entitled "Computer-Aided Diagnosis of Epilepsy Using Clinical Information" outlining advances in the use of computational machine learning to help clinicians detect and diagnose epilepsy correctly.

"A large fraction of patients with seizure disorder are misdiagnosed and treated inappropriately," Cohen said. "As such treatments carry their own risks and negative side effects, their research could positively affect the lives of millions of Americans."

The goal of Kerr's team was to estimate the probability of epilepsy versus non-epileptic seizures based on the historical factors reported by the patient to their neurologist.

Distinguishing between epileptic and non-epileptic seizures is a challenge, Kerr said. On average, the time from the first seizure to the diagnosis of non-epileptic seizures is seven years. In the meantime, a majority of those patients are misdiagnosed with epilepsy and treated inappropriately with anti-epileptic medications.

"This can expose patients to serious, and potentially fatal, side effects," Kerr said. "One of our laboratory's goals is to create an automated system that can aid physicians in distinguishing patients with epileptic and non-epileptic seizures."

Kerr and his team accomplished this by inspecting outpatient clinical notes from patients with medication-resistant seizure disorder, who were later diagnosed as having epilepsy or non-epileptic seizure disorder, using the gold standard diagnostic assessment, 72- hour in-patient closed circuit video-electroencephalography (VEEG) monitoring.

Using a combination of the known risk factors for epilepsy and non-epileptic seizures reported in 228 clinical notes the team examined, their algorithm achieved a diagnosis accuracy of 65%. While at first glance this may appear low, it is comparable to the accuracy of neurologists prior to VEEG monitoring. In this work, they used a machine learning method known as a "decision tree."

"The structure of our decision tree also provided meaningful information about the interpretation of each risk factor in each patient. For example, the risk factors for non-epileptic seizures may not be the same for women and men," Kerr said. "This work may help diagnose, and thereby more effectively treat, patients that are in need."

In addition to serving patients with seizure disorder, the computer-aided diagnostic methods developed by Kerr and his team may be applicable to the diagnosis of other maladies in the future.

*The Posters on the Hill exhibit typically picks just one or two research projects per state to participate in the event, said Mark Cohen, Kerr's faculty advisor and a professor-in-residence of psychiatry in the Semel Institute for Neuroscience and Human Behavior. As part of their trip, Patel, Barritt and Kerr will take meetings in the offices of California state senators and representatives. They will use this forum to emphasize the importance of appropriate diagnosis in epilepsy and the academic environment at UCLA that made this research possible.


Story Source:

The above story is based on materials provided by University of California - Los Angeles Health Sciences. Note: Materials may be edited for content and length.


Cite This Page:

University of California - Los Angeles Health Sciences. "Epileptic or non-epileptic seizures? Misdiagnosis common." ScienceDaily. ScienceDaily, 28 April 2014. <www.sciencedaily.com/releases/2014/04/140428171528.htm>.
University of California - Los Angeles Health Sciences. (2014, April 28). Epileptic or non-epileptic seizures? Misdiagnosis common. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/04/140428171528.htm
University of California - Los Angeles Health Sciences. "Epileptic or non-epileptic seizures? Misdiagnosis common." ScienceDaily. www.sciencedaily.com/releases/2014/04/140428171528.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins